The Technical Analyst
Nabriva Therapeutics PLC [NBRV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Nabriva Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.71% $1.420
America/New_York / 31 jul 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.55 mill |
| EPS: | -19.67 |
| P/E: | -0.0722 |
| Earnings Date: | Aug 09, 2023 |
| SharesOutstanding: | 3.20 mill |
| Avg Daily Volume: | 0.0138 mill |
| RATING 2023-08-29 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0722 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0722 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.449 - 0.811 ( +/- 28.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-06 | Hogan H Michael Iii | Buy | 0 | |
| 2023-06-30 | Maggio David | Buy | 0 | |
| 2023-01-29 | Gelone Steven P. | Sell | 140 | Ordinary Shares |
| 2023-01-29 | Schroeder Theodore R | Sell | 431 | Ordinary Shares |
| 2023-01-06 | Gelone Steven P. | Sell | 5 | Ordinary Shares |
| INSIDER POWER |
|---|
| 20.46 |
| Last 98 transactions |
| Buy: 1 927 900 | Sell: 612 376 |
Forecast:
01:40 - $1.069
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.420 (0.71% ) |
| Volume | 0.707 mill |
| Avg. Vol. | 0.0138 mill |
| % of Avg. Vol | 5 103.92 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NBRV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Latest Press Releases
2022-11-07 07:01:00 - Press Release
Nabriva Therapeutics To Report Third Quarter 2022 Financial Results And Recent Corporate Highlights On November 10, 2022
Dublin, ireland and fort washington, pa., nov. 07, 2022 (globe newswire) -- nabriva therapeutics plc (nasdaq: nbrv), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the u.s. financial markets on thursday, november 10, 2022. nabriva's management will host a conference call at 4:30 p.m. et to discuss the financial results and recent corporate highlights.
2022-09-15 07:01:00 - Press Release
Nabriva Therapeutics Announces Date Of 1-for-25 Reverse Stock Split
Dublin, ireland and fort washington, pa., sept. 15, 2022 (globe newswire) -- nabriva therapeutics plc (nasdaq: nbrv), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the nasdaq capital market as of the commencement of trading on september 16, 2022.
2022-09-06 07:01:00 - Press Release
Nabriva Therapeutics To Participate In The H.c. Wainwright 24th Annual Global Investment Conference
Dublin, ireland and fort washington, pa., sept. 06, 2022 (globe newswire) -- nabriva therapeutics plc (nasdaq: nbrv), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that ted schroeder, chief executive officer at nabriva, will provide a company overview and business update at the h.c. wainwright 24th annual global investment conference. management will also host investor meetings september 12-14, 2022.
2022-07-20 16:05:00 - Press Release
Nabriva Therapeutics To Report Second Quarter 2022 Financial Results And Recent Corporate Highlights On August 3, 2022
Dublin, ireland and fort washington, pa., july 20, 2022 (globe newswire) -- nabriva therapeutics plc (nasdaq: nbrv), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the u.s. financial markets on wednesday, august 3, 2022. nabriva's management will host a conference call at 4:30 p.m. et to discuss the financial results and recent corporate highlights.
2022-05-13 07:01:00 - Press Release
Nabriva Therapeutics To Present At The H.c. Wainwright Global Investment Conference
Dublin, ireland, may 13, 2022 (globe newswire) -- nabriva therapeutics plc (nasdaq: nbrv), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that ted schroeder, chief executive officer at nabriva, will provide a company overview and business update at the h.c. wainwright global investment conference. the presentation will be available on-demand beginning on tuesday, may 24 at 7:00 am et. management will also host investor meetings may 24-26, 2022.
Latest News
2023-03-20 18:20:26 - InvestorPlace
7 Stocks to Sell as Banks Melt Down
Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.
2022-11-29 14:18:12 - Zacks Investment Research
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
2022-11-28 08:20:53 - Market Watch
Nabriva's stock is up after sharing antibiotic news
Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia.
2022-11-13 19:40:40 - Seeking Alpha
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
Nabriva Therapeutics plc (NASDAQ:NBRV ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Ed Arce - H.C. Wainwright Operator Welcome to the Nabriva Therapeutics Third Quarter 2022 Financial Results Call and Corporate Update.
2022-11-07 07:01:00 - GlobeNewsWire
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.
2022-09-16 11:30:21 - InvestorPlace
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?
Source: iQoncept / Shutterstock Nabriva Therapeutics (NASDAQ: NBRV ) stock caught the attention of traders on Friday after shares surged in price this morning. However, not all is as it seems.
2022-09-16 06:00:00 - PennyStocks
Buying Penny Stocks Today? What You Need to Know
Here's what you need to know about trading penny stocks on September 16th The post Buying Penny Stocks Today? What You Need to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-15 08:05:35 - Pulse2
Nabriva Therapeutics (NBRV) Stock: 1-For-25 Reverse Stock Split Announced
Nabriva Therapeutics (NBRV) announces it will effect a 1-for-25 reverse stock split. These are the details.
2022-09-15 07:01:00 - GlobeNewsWire
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022.
2022-09-14 13:29:10 - Zacks Investment Research
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).